Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 725

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 725
---
 ​ | ​ | Name:           | ​ | ​ | Sumit Mehta               | ​ |
| ​ | ​ | ​ | ​ | ​                             | ​ | ​ | Title:          | ​ | ​ | Authorized Representative | ​ |

D-5

TABLE OF CONTENTS

Exhibit A Shareholders

| Shareholder                   | ​ | ​ | Number of Shares of Common Stock | ​ | ​ | Address for Notices          | ​ |
| Iris Acquisition Holdings LLC | ​ | ​ |                        6,900,000 | ​ | ​ | 3rd Floor Zephyr House       
 122 Mary Street, George Town 
 PO Box 10085                 
 Grand Cayman KY1-1001,       
 Cayman Islands               | ​ |

D-6

TABLE OF CONTENTS

#### Annex E​

#### EXECUTION VERSION​

### SUBSCRIPTION AGREEMENT
This SUBSCRIPTION AGREEMENT (this “ Subscription Agreement ”) is entered into on November 28, 2022, by and among IRIS Acquisition Corp., a Delaware corporation (“ IRIS ”), IRIS Parent Holding Corp., a Delaware corporation (“ Issuer ” or “ ParentC o”) and the undersigned subscriber (“ Subscriber ”).

WHEREAS, concurrently with the execution of this Subscription Agreement, IRIS, ParentCo, Liminatus Pharma, LLC, a Delaware limited liability company (“ Liminatus ”), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“ Liminatus Merger Sub ”), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“ SPAC Merger Sub ”) are entering into a Business Combination Agreement (as amended, modified, supplemented or waived from time to time, the “ Transaction Agreement ” and the transactions contemplated by the Transaction Agreement to be completed on and prior to the closing date thereof, collectively, the “ Transaction ”), pursuant to which, among other things, in the manner, and on the terms and subject to the conditions and exclusions set forth therein, effective as of the closing of the Transaction, (a) Liminatus Merger Sub will merge with and into Liminatus, with Liminatus surviving as a direct wholly-owned subsidiary of ParentCo (the “ Company Merger ”), and (b) simultaneously with the Company Merger, SPAC Merger Sub will merge with and into IRIS, with IRIS surving as a direct wholly-owned subsidiary of ParentCo (the “ SPAC Merger